Telomerase activity as an adjunct to high-risk human papillomavirus types 16 and 18 and cytology screening in cervical cancer by Kailash, U. et al.
Telomerase activity as an adjunct to high-risk human
papillomavirus types 16 and 18 and cytology screening in cervical
cancer
U Kailash1, CC Soundararajan2, R Lakshmy3, R Arora4, S Vivekanandhan2 and BC Das*,1
1Division of Molecular Oncology, Institute of Cytology and Preventive Oncology (ICMR), Sector 39, NOIDA – 201301, UP, India; 2Department of
Neurobiochemistry, All India Institute of Medical Sciences, New Delhi 110029, India; 3Department of Cardiac Biochemistry, All India Institute of Medical
Sciences, New Delhi 110029, India; 4Department of Obstetrics and Gynecology, Lok Nayak Hospital, Maulana Azad Medical College Campus, Bahadur
Shah Zafar Marg, New Delhi 110002, India
Telomerase is a ribonucleoprotein comprising an RNA template, the telomerase-associated protein and its catalytic subunit, human
telomerase reverse transcriptase (hTERT). Telomerase activation is a critical step in cellular immortalisation and development of
cancer. Enhanced telomerase activity has been demonstrated in cervical cancer. In the present study telomerase activity and hTERT
mRNA expression were evaluated and correlated with the presence of human papillomavirus (HPV) infection and cytological
changes in the cervical lesions. Telomerase activity was assayed by telomeric repeat amplification protocol, hTERT mRNA expression
by reverse transcriptase polymerase chain reaction and presence of high risk HPV (HR-HPV) infection by polymerase chain reaction.
Out of 154 cervical samples of different cytology, 90 (58.44%) were positive for HR-HPV types 16/18, while among 55 normal
cervical scrapes, 10 (18.18%) were HPV DNA positive. All 59 invasive cancer samples showed a very high telomerase activity. Among
dysplasia, seven (63.6%) mild dysplasia, 18 (100%) of moderate, 20 (100%) of severe dysplasia and 6 (100%) carcinoma in situ (CIS)
samples were positive with mild to moderate to high to very high telomerase activity respectively. Seven (12.7%) samples of
apparently normal cervical scrapes were weakly positive for telomerase activity. We observed a good correlation (Po0.001)
between telomerase activity and HR-HPV 16/18 positivity with a sensitivity of 88.1% for HPV and 100% for telomerase activity. It is
suggested that telomerase activity may be used as an adjunct to cytology and HPV DNA testing in triaging women with cervical
lesions.
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Cervical cancer is one of the most common causes of mortality
among women worldwide with an annual incidence rate of
approximately 400 000 cases and 200 000 deaths per year (Parkin
et al, 2001). The greatest burden of the disease is in developing
countries where lack of organised screening facility contributes to
nearly one quarter of all female cancers. In developed countries
Pap smear screening is associated with a 75% reduction in the
incidence of cervical cancer (Kurman et al, 1994).
Clinical and molecular epidemiological studies demonstrated
convincingly that certain types of human papillomaviruses (HPVs)
are the primary causal agents in the development of cervical
carcinoma (Bosch and de Sanjose, 2002; Munoz et al, 2003). So far,
more than 100 different types of HPV have been found and their
nucleotide sequences have been characterised. Among them, 30
types have been linked to the development of anogenital cancers.
Human papillomavirus types have been classified into ‘low’ and
‘high’ risk types based on their potential to induce tumourigenic
transformation. HPV types 16,18,31,33,35,39,45,51,52,56,58,59,68,
73 and 82 are considered as high risk types while 6,11,40,42,43,
44,54,61,70,72,81 and CP6 108 as low risk types (Munoz et al,
2003). Among high risk HPV types, HPV 16 and 18 are considered
to be carcinogenic agents and are strongly implicated with the
development of cervical cancer (IARC Monographs Working
Group, 1995; zur Hausen, 2001).
Studies on the oncogenic potential of these HPV types have
clearly demonstrated that HR-HPVs are a necessary cause for the
development of cervical cancer (Schiffman et al, 1993; Bosch et al,
1995) but only a small proportion of women with cytological
abnormalities or infected with HR-HPV types will eventually
progress to invasive cancer with majority of infections is cleared
spontaneously, which suggests the view that although infection
with HPV is essential but it may not be sufficient for the
development of cervical cancer. Only persistent HPV infection may
lead to the development of invasive cervical cancer. Screening of
cervical cancer is essentially carried out by the Pap smear test,
which although effective in detecting high risk premalignant and
malignant cervical cells, it suffers from high false negative rates,
intra- and interpersonnel and laboratory variations. New screening
strategies, including testing for HR-HPV DNA as an adjunct to
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cytology to triage and monitor cervical lesions have been
advocated. Involvement of other cellular and molecular events in
the HPV-induced cervical carcinogenesis turned the focus to
identify other molecular markers for effective screening and
diagnosing cervical pre and invasive malignancies.
Recent observations support the concept that activation of
telomerase is a critical step in cellular immortalisation and cancer.
Telomeres, the ends of chromosomes are specialised DNA-protein
complexes, composed of TTAGGG repeats. They play an important
role in genomic integrity and stability by preventing the
recognition of chromosomal ends as double-stranded DNA breaks.
Telomerase synthesises (TTAGGG)n DNA repeats onto chromo-
some ends. It is a ribonucleoprotein complex, consisting of an
internal RNA component human telomerase RNA (hTR), a
catalytic protein subunit, human telomerase reverse transcriptase
(hTERT) and other associated proteins namely hTP1 etc. Most
adult somatic cells exhibit low or no telomerase activity and thus
experience progressive telomere attrition with each round of cell
cycle. In contrast, germline cells, differentiating cells and tumour
cells have elevated or detectable levels of telomerase activity and
have long or stable telomeres. Consequently, telomerase may be
required for the long-term proliferation of tumours. Stabilisation
of telomere lengths by activation of telomerase is thought to be the
key mechanism of indefinite cell proliferation and immortalisa-
tion. Telomerase activity has been reported in different tumour
types (Kim et al, 1995). Elevated levels of telomerase activity have
been detected in invasive cervical carcinomas, as well as in high-
grade cervical dysplasias. A few investigators also reported low
telomerase activity in normal, inflammatory and premalignant
cervical lesions (Zheng et al, 1997; Wisman et al, 2000).
The main transforming genes of HPV 16 and other HR-HPV
types are E6 and E7. HPV E6 protein generally target and degrade
tumour-suppressor protein, p53, through ubiquitin pathway
(Scheffner et al, 1990, 1993; Werness et al, 1990). However, it
has also been reported to bind to a number of other cellular
proteins and has functions that are independent of p53 degrada-
tion including the activation of telomerase (Rapp and Chen, 1998).
Sprague et al (2002) indicated that HPV-16 by itself does not
necessarily cause telomerase activation in cervical keratinocytes,
but rather, supports a model in which HPV-16 facilitates
telomerase activation in conjunction with other viral or cellular
changes over time. Given that HPV infection has been associated
with majority of the cases of invasive cervical cancers, it may be
deduced that, telomerase activation may be a critical pathway by
which HPV infection facilitates malignant transformation of the
cervical epithelium, making it an ideal marker for cervical cancer
screening. In India, cancer of the uterine cervix is the major cancer
in women and infection of HPV has been detected in more than
98% cases (Das et al, 1992a, b). There are, however, only a few
studies from India where an attempt has been made to augment
skeletal cervical cytology screening programme. Recently, Arora
et al (2005) suggested that HR-HPV detection can be utilised as an
adjunct to routine cytology screening programmes to identify ‘high
risk’ women who have concurrently negative Pap smears but may
harbour oncogenic HPV infection and/or are more likely to
develop cervical intraepithelial neoplastic lesions.
In the present study, we investigated whether the status of HPV
infection, telomerase activity, hTERT, hTR and hTP1 mRNA
expressions in cervical tissues and/or cervical scrapes have clinical
value in the triage of women or useful as an adjunct to cytology,
particularly undefined or atypical squamous cells of undetermined
significance (ASC-US) and mild, moderate or severe dyskaryosis.
MATERIALS AND METHODS
This study was conducted in 154 tissue biopsies from patients in
the age group 25–60 years and included 59 invasive cervical
carcinomas, 55 dysplastic tissues belonging to various grades
namely, mild (n¼ 11), moderate (n¼ 18), severe dysplasias
(n¼ 20) and CIS (n¼ 6) cases and 40 normal cervical tissue
controls. The study also included 55 cervical scrapes from
asymptomatic, normal healthy women. All the biopsies were
colposcopy-directed, and were either histopathologically or
cytologically confirmed by the pathologists. Before taking punch
biopsy, cervical scrapes were taken from all invasive cancer
patients.
The biopsy specimens of cervical carcinomas were collected
from women attending the ‘cancer clinic’ at Obstetrics and
Gynaecology out-patient department (OPD) of Lok Nayak
Hospital, New Delhi. The clinical staging of the tumours ranged
from stage I to stage IV and their histological tumour grading was
either of poor, moderate or well-differentiated squamous cell
carcinomas and adenocarcinomas and subtypes thereof. Control
biopsy specimens were collected from asymptomatic, apparently
normal women visiting OPD and undergoing hysterectomy for
gynaecological reasons other than cervical cancer such as fibroids,
dysfunctional uterine bleeding etc. Cervical scrapes were also
collected from asymptomatic normal women coming for checkups
other than gynaecological complaints. Informed consent was
obtained from each patient before recruitment for the study.
Biopsies and the scraped cervical cells were collected in chilled
PBS and transported from cancer clinic to the laboratory on ice.
Each biopsy specimen was bisected after grossing by pathologists;
one-half was subjected to histopathological examination after
fixing the sample in 10% formaldehyde. The remaining half was
employed for DNA and RNA extraction. The whole procedure was
completed within 3 h from the time of collection.
HPV analysis
Genomic DNA was extracted from the cervical tissues/scrapes
using Proteinase K/phenol-chloroform method. Human papillo-
mavirus detection was carried out by polymerase chain reaction
(PCR), using the consensus primers MY09 and MY11, with an
expected product size of about 450 base pairs (bp), for the
amplification of the most conserved LI region of the HPV genome.
A gene fragment of the b-globin was used as an internal control to
check the integrity of the specimens. Further HPV typing was
carried out using type-specific primers for HPV types 16, 18, 6 and
11 (Das et al, 1992a). Polymerase chain reaction products were
separated electrophoretically on an ethidium bromide stained 3%
Nusieve agarose gel. Each PCR reaction included a positive and a
negative control.
Estimation of telomerase activity by TRAP assay
A portion of the tissue grinded in liquid nitrogen (40– 100 mg) was
suspended in 200 ml ice-cold CHAPS lysis buffer (10 mM Tris-HCl
pH 7.5, 1 mM MgCl2, 0.1 mM phenylmethylsulphonyl fluoride, 1 mM
EGTA, 5 mM b-mercaptoethanol, 0.5% CHAPS and 10% glycerol).
After 30 min of incubation on ice, lysates were centrifuged at
10 000 r.p.m. for 20 min at 41C, the supernatant was aliquoted and
stored at 701C until used for assay.
Telomeric repeat amplification protocol (TRAP) assay was
carried out as described by Kim et al (1995) with minor
modifications in 50 ml reaction mixture containing (20 mM Tris-
HCl (pH 8.3), 1.5 mM MgCl2, 63 mM KCl, 0.005% Tween-20, 1 mM
EGTA, 50mM each of dNTPs, 1mg of T4 gene 32 protein (Boehringer
Mannheim, Mannheim, Germany), bovine serum albumin
(1 mg ml1), 0.1mg of TS primer (50-AATCCGTCGAGCAGAGTT-
30) and [a-P32]dCTP10Ci/ml (specific activity 3000 Ci mmole1) with
5mg of protein. After telomerase mediated strand formation 0.1mg
of CX primer was added at 721C and PCR amplification was
performed. Lysate from HeLa cells were used as positive control.
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Sample treated with RNAse A was treated as negative control. Lysis
buffer was used as reagent blank to monitor reagent contamination.
The PCR products were then analysed by electrophoresis on
12% polyacrylamide nondenaturing gel and autoradiographed. The
level of telomerase activity was quantified by comparing the
density of the ladder signals with the positive control (HeLa cells)
and expressed in relative units (RU). Samples which did not give
ladder were comparable to negative control and were graded as 0,
the ladder which gave stronger signal compared to positive signal
as 4þ (þ þ þ þ ), equal signal as 3þ , moderate as 2þ and mild
in 1þ RU.
Expression analysis of telomerase components hTERT,
hTR and hTP1
RNA was extracted from the tissue biopsies using TRI reagent
according to the manufacturer’s specifications. The cDNA was
synthesised for each of the sample using 5 mg ml1 of RNA. The
reaction was carried out in 20 ml containing 50 ng of random
hexamer primers (N6) (Bangalore Genei, Bangalore, India),
250mmol of each of nucleotides (dATP, dCTP, dGTP and dTTP),
0.1 M of dithiothreitol, 40 Uml1 of RNAse inhibitor (Life
Technologies, Carlsbad, CA, USA) and MMLV reverse transcrip-
tase (Gibco BRL, NY, USA). The cDNAs were stored at 701C until
PCR amplification.
Two microlitre of cDNA was taken in a total volume of 50 ml
reaction mixture, containing 10 mM dNTPs, 10 mM of each set of
primers, 5 U of Taq DNA polymerase, by using gene-specific
primers for hTERT, hTR and hTP1 along with the primers for
glyceraldehyde-3-phosphate dehydrogenase (G3PDH). The cDNA
was amplified for 36, 32 and 30 cycles, respectively, for hTERT,
hTR, hTP1 along with house keeping gene G3PDH. The amplified
PCR products were resolved by electrophoresis on ethidium
bromide stained 1.5% agarose gel and visualised in BIO-RAD gel
documentation system.
RESULTS
Detection of HPV by PCR
In all, 52 out of 59 invasive cervical carcinomas (88.1%), 38 of 55
(69.1%) dysplasias, two (5%) out of 40 normal control tissues and
13 of 55 (23.6%) normal cervical scrapes were positive for HPV
by LI consensus primers. Further typing of HR-HPV 16 and 18 was
carried out by PCR amplification of most conserved upstream
regulatory region (URR) sequence of HPV 16, which results in a
PCR product of 217, and 100 bp band HPV 18 E6 region (Figure 1).
Table 1 demonstrates, out of 59 cervical tumour biopsies, 50
(84.7%) were positive for HPV type 16 and two (3.39%) for HPV
type 18. None of the invasive tumour samples showed amplifica-
tion for other two HPV types (6 and 11). Thus, the positivity for
HR-HPV types 16/18 as revealed by PCR was 88.14%. Polymerase
chain reaction amplification of 55 cervical dysplasia samples
revealed 36 cases (65.4%) of HPV type 16. The break-up of HPV
type 16 positivity among dysplasia cases was six (54.5%) of mild,
10 (55.5%) of moderate, 20 (76.9%) of severe dysplasia which
include five cases of CIS, respectively. two samples (5%) of normal
control tissues were positive for oncogenic HPV type 16 and
remaining 38 samples were negative for any type of HPV infection
as revealed by consensus primers. Polymerase chain reaction
amplification for HPV 16 in normal cervical scrapes revealed 10
(18.18%) positive cases out of which one sample (1. 81%) was also
positive for HPV 18 (Table 1).
Telomerase activity
All 59 (100%) invasive cervical tumours showed a very high
telomerase activity when compared to that of controls (5%).
Cervical smears from the same patients also showed similar
increased activity. Of the 55 dysplasia samples, seven (63.6%) of 11
mild dysplasia, samples revealed low telomerase activity. While all
18 (100%) moderate, 20 (100%) of severe dysplasia and six (100%)
of CIS cases were positive for moderate to high to very high
telomerase activity respectively. Out of 40 normal control tissues
only two (5%) were positive for telomerase activity but seven cases
(12.7%) of apparently normal cervical scrapes showed weak
telomerase activity. Telomerase activity in different cervical lesions
is shown in Figure 2.
Telomerase activity and HPV status in cervical lesions
Table 1 demonstrates associations, sensitivity and specificity of
telomerase activity and HPV status in normal and abnormal
cervical lesions. The HR-HPV 16/18 infection (OR 141.1, Po0.001)
showed 88.1% sensitivity in invasive carcinomas compared to
100% sensitivity of telomerase activity. It is further observed that
as the positivity of oncogenic HPV types 16/18 increased
telomerase activity also increased with the increased severity of
the disease. Severe dysplasia cases showed 100% sensitivity for
telomerase activity compared to 76.9% for HPV. Telomerase
activity thus appears to be a better molecular marker than HR-
HPV 16/18 in detecting lesions even in mild dysplasia cases.
Table 2 shows 88.1% concordance between telomerase activity and
HPV status in invasive cervical carcinomas, 69.1% in dysplasias
and 100% in normal cervical tissues. The extent of agreement in
positivity among ‘normal’ scrape samples of 55 women also
showed a good concordance (94.5%) between HPV and telomerase
methods.
Expression analysis of telomerase components hTERT,
hTR and hTP1
RT–PCR experiments for hTERT, hTR and hTP1 mRNA expres-
sions revealed that both hTR and hTP1 were constitutively
expressed in all invasive carcinomas, dysplastic lesions and
normal controls of the uterine cervix. However, the expression of
hTERT levels was greater in invasive cervical cancer samples and
showed an increasing trend with the increasing grade of dysplasia/
cervical cancer (Figure 3).
As regards to hTERT, a very high expression levels was observed
in all 59 invasive cervical carcinomas, which also well correlated
with their high telomerase activity. Human telomerase reverse
transcriptase expression in eight mild, 18 moderate, 20 severe
dysplastic lesions and six CIS cases ranged from mild to moderate
Lanes 3–9: Amplimers of 217bp HPV 16 and 268 bp -globin gene in
cervical tumour DNA samples. Lane M: HaeIII-digested ×174 DNA
molecular weight marker 
M PC 1 32 4 5 6 7 8
268 bp
217 bp
DNA as negative control showing amplification of only -globin gene.
amplification of desired amplimer of 217bp. Lane 1:  Placental
Positive control. IIPV 16 vector-free DNA showingLane PC:
Figure 1 Simultaneous PCR amplification of (1) HPV 16 URR and b-
globin gene in cervical cancer DNA samples.
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to high and very high levels, respectively. While seven samples of
normal cervical scrapes revealed a weak hTERT mRNA expression,
none of the normal control tissue samples had any detectable levels
of hTERT expression. A specific PCR amplimer of 145 bp for
hTERT and a 103 bp for hTR are shown in Figure 3. The extent of
hTERT expression shows a significant correlation with the level of
telomerase activity and the grade of the disease (Po0.001).
hTERT, hTR and hTP1 mRNA expressions in relation to
HPV
When HPV infection in the different categories of cervical lesions
was correlated with the expression of telomerase components
hTERT, hTR and hTP1 as determined by RT–PCR, a good
correlation with the presence of oncogenic HPV type 16 was
observed. Human telomerase reverse transcriptase expression was
detected in as many as 88 of 90 (97.8%) specimens which were
positive for HR-HPV type 16, with the exception of only one
(1.11%) of HPV-positive samples not expressing hTERT
(Po0.001). Human telomerase RNA and hTP1 expressions were
found even in HPV negative samples, although not as high as in
HPV-positive samples. However, their expression levels increased
with increasing severity of the disease.
Statistics
The Fisher’s exact test was used for comparisons between groups.
Statistical analysis was carried out using SPSS (version 10)
software.
Table 1 Telomerase activity in relation to HPV status in invasive, dysplastic and normal cervical lesions
Type of cervical lesion
HR-HPV 16/18 Telomerase activity
Positve Negative OR (P-value) Positive Negative OR (P-value)
(a) (b) (c) (d) (e) (f) (g)
Invasive cervical carcinomas (n¼ 59) 52 (88.1%) 7 (11.9%) 141.1 (o0.001) 59 (100.0%) 0 —a (o0.001)
Severe (Severe dysplasia and CIS) (n¼ 26) 20 (76.9)% 6 (23.1%) 63.3 (o0.001) 26 (100%) 0 —a (o0.001)
Moderate (n¼ 18) 10 (55.5%) 8 (44.5%) 23.8 (o0.001) 18 (100%) 0 —a (o0.001)
Mild dysplasia (n¼ 11) 6 (54.5%) 5 (45.5%) 22.8 (o0.001) 7 (63.6%) 4 (36.4%) 32.3 (o0.001)
Normal cervical tissues (n¼ 40) 2 (5.0%) 38 (95.0%) — 2 (5%) 38 (95.0%) — (o0.001)
HPV¼ human papillomaviruses; HR-HPV¼ high risk HPV; OR¼ odds ratio. In column (b) and (e) percentages for abnormal lesions indicate sensitivities. In column (c) and (f)
percentages for normal lesion indicate specificity. aOR could not be calculated due to 0 cell value.
Table 2 Association between telomerase activity and HPV status in invasive, dysplastic and normal cervical lesions
Telomerase activity
Invasive carcinomas (n¼ 59) Dysplasias (n¼ 55) Normal (40)
HPV status Present Absent Total Present Absent Total Present Absent Total
Positive 52 (100%) 0 (0%) 52 34 (94.4%) 2 (5.6%) 36 2 (100%) 0 (0%) 2
Negative 7 (100%) 0 (0%) 7 15 (78.9%) 4 (21.1%) 19 0 (0%) 38 (100%) 38
Total 59 0 59 49 (89.1%) 6 (10.9%) 55 2 38 40
% Agreement between HPV and telomerase activity 88.1 69.1 100
HPV¼ human papillomaviruses. Figures in parenthesis indicate percentages out of HPV status.
Lane PC:  Positive control (HeLa cells). Lane NC:  Negative control 
(sample treated with RNAse A). Lanes 1–7:  Invasive cervical tumour
samples showing telomerase activity.
PC NC 1 2 3 4 5 6 7
Figure 2 Telomerase activity in cervical tumour tissues. Tissue extracts
showing 6 bp ladder from TRAP assay depicting telomerase activity.
Lanes 1–9:  Cervical tumour samples showing hTERT (145 bp) and
hTR (103 bp) mRNA expression. Lane M:  HaeIII-digested ×174  
DNA molecular weight marker 
145 bp
103 bp
M 1 2 3 4 5 6 7 8 9
Figure 3 RT–PCR showing hTERT and hTR expression in cervical
tumour tissues.
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DISCUSSION
We studied the relationship between HPV status, telomerase
activity, hTERT, hTR, hTP1 mRNA expression during the
development of cervical cancer through different grades of cervical
dysplasia to invasive cervical cancer.
Cytology is considered as the gold standard for the diagnosis of
dysplastic and invasive uterine cervical lesions. Pap smear test
routinely employed for the diagnosis of premalignant cervical
lesions is, however, found to have variable sensitivity and
specificity. Testing for oncogenic type of HPVs is another viable
method to screen women with cytological abnormalities since HR-
HPV infections are considered as the most common causal factor
and are reported in more than 90% of cervical cancers (Das et al,
1992b; Bosch et al, 1995; Bosch and de Sanjose, 2002). We have
considered only four HPV types (HPV 16,18,6 and 11) that are
highly prevalent in and around Delhi for this study. HPV types 16
and 18 constitute almost 90% of cervical cancers in India and the
presence of other high risk types is very low or nil (Das et al,
1992a, b; Gopalkrishna et al, 2000; Franceschi et al, 2005). It has
been reported that 10– 35% of normal healthy women harbour
HPV DNA in their cervical epithelium depending on the screening
method, age of the women, number of subjects studied and their
geographic locations (Lorincz et al, 1986, 1992; Toorn et al, 1986).
In the present study only 5% of normal control tissues (n¼ 40)
compared to 18% of (n¼ 10) normal cervical scrapes were positive
for HR-HPV types 16/18 infection. This observation in the present
study is interesting. It is possible that these women who were
attending OPD with symptomatic complaints, may not really be
normal women in strict sense, thus they may be having latent or an
occult or commensal papillomavirus infection, that is, the presence
of HPV DNA in the absence of a visible, histologic or cytologic
abnormality. Oriel (1971) coined the lag period between exposure
to HPV infection and development of clinical disease as ‘latent
infection’, which was approximately 4 months, which is corrobo-
rated by Kreider et al (1987) experimentally, in their studies. The
reason may be that the virus might be present in latent state and/or
in unintegrated form without affecting cellular morphology, which
shows up in Pap test. This transient infection may be cleared by
immune system in majority of women in due course of time.
However, those persisting may be integrated into the host cell
genome and progress to carcinoma. It is also known that
transformation of HPV appears to involve HPV DNA integration
into host genome. Further the progress and outcome of an HPV
infection depend on the HPV type, viral load and the nature and
timing of local and tissue influences (Cheng et al, 1995; Jian et al,
1998).
HPV type 16 was found to be the most prevalent type (84.7%)
which is in agreement with other studies, while the frequency of
HPV type 18 (3.38) is very low when compared to other ethnic
population (Durst et al, 1983; Yoshikawa et al, 1985; Das et al,
1992b; Bosch et al, 1995; Clifford et al, 2003) but it is consistent
with Indian data (Das et al, 1992a, b). Absence of any HPV type in
seven cervical tumours indicates that some other mechanism/
factors or a hitherto unknown HPV-dependent pathway also exists
for the genesis of cervical cancer. The overall HPV positivity in 55
cervical dysplastic lesions including carcinoma-in-situ was 69.1%.
The results were comparable to earlier published reports (van Den
Brule et al, 1991; Cornelissen et al, 1992; Cuzick et al, 1994;
Holowaty et al 1999; Voglino et al, 2000; Reddy et al, 2001). The
positivity of high risk HPVs 16 and 18 was found to be 64.5%. One
CIS sample was positive for both HPV 16 and HPV 18. The break
up of HR-HPV type 16 positivity in mild, moderate, severe and in
CIS was 54.5, 55.5, 75.0 and 83.3%, respectively. Similar prevalence
was shown for HPV type 16 and 18 in dysplastic lesions by other
authors (van Den Brule et al, 1991; Cornelissen et al, 1992; Cuzick
et al, 1994; Holowaty et al, 1999; Voglino et al, 2000). Observation
of a higher frequency of HR-HPV types in women with severe
dysplastic lesions and CIS than in mild dysplsia is also in
agreement with earlier reports (McCance et al, 1985; Cornelissen
et al, 1992; Cuzick et al, 1994; Delvenne et al 1994). Gradual
increase in the frequency of high risk HPV types 16 and 18 from
mild to moderate to severe dysplastic lesions to invasive cervical
cancer suggests that the frequency of high risk HR-HPV infection
changes as a function of severity of cervical lesions.
Besides being an important risk factor for cervical cancer, HPV
has been found to activate telomerase with its E6 oncoprotein
(Klingelhutz et al, 1996). Ex vivo studies showed that transfection
of normal epithelial cervical keratinocytes with the HPV E6 gene
resulted in telomerase activation even before the occurrence of
‘crisis’ (Klingelhutz et al, 1996). It has been observed that low-
grade dysplasias with the infection of HR-HPV 16 and 18 showed a
higher rate of progression to malignancy (Reid et al, 1987; Das
et al, 1989; Cuzick et al, 1992). It suggests that those early lesions
infected with high risk HPV 16 could be induced to progress
because of induction of telomerase activity by their E6 onco-
protein.
Activation of telomerase at a site, which is normally telomerase
negative, indicates the presence of immortal or malignant cells
(Hiyama et al, 1995; Sommerfield et al, 1996). Reddy et al (2001)
reported 100% telomerase positivity in 29 cases of cervical
intraepithelial neoplasia (CIN) IB, IIB, IIIA and IIIB. Several
authors (Kyo et al, 1997; Meeker and Coffey, 1997; Zheng et al,
1997; Shroyer et al, 1998; Wisman et al, 2000) in survey on human
malignancies reported 88–100% telomerase activity. Cervical
cancers exhibit high telomerase activity irrespective of histo-
pathology grading but the intensity/level of telomerase activity
increased with the clinical progression of the disease.
In the present study, we observed weak telomerase activity in
seven (64.6%) of 11 mild dysplasia samples. All 18 moderate, 26
severe dysplasias which included six CIS samples were positive for
moderate to high to very high telomerase activity, respectively.
High telomerase activity in all samples of CIS, at par with invasive
carcinomas, is justified since this stage is a pre-invasive stage.
Similar results were reported by several other authors (Kyo et al,
1997; Zheng et al, 1997; Shroyer et al, 1998; Zhang et al, 1999;
Wisman et al, 2000). Meeker and Coffey (1997) noted 46%
telomerase positivity in cervical precancerous tissues where as
Snijders et al (1998) reported low telomerase positivity in CIN
lesions. The high percentage of telomerase activity in the present
study group may be due to the presence of more number of severe
dysplasia cases. The very presence of telomerase activity in the
preneoplastic cervical tissues indicates that telomerase is activated
early in the course of cervical carcinogenesis and may be a vital
constituent of malignant progression. The HR-HPV 16/18 infection
showed 88.1% sensitivity in invasive carcinomas compared to
100% sensitivity of telomerase activity. It is further observed that
as the positivity of oncogenic HPV types 16/18 increased
telomerase activity also increased with the increased severity of
the disease. Severe dysplasia cases showed 100% sensitivity for
telomerase activity compared to 76.9% for HPV. This indicates a
good association between HPV infection and activation of
telomerase during cervical carcinogenesis.
Cervical scrapes collected from the same cervical cancer patients
(n¼ 59) also revealed similar results suggesting that the telomerase
activity of exfoliated cells reflects that of the lesions or tumour
tissues. This is a very interesting finding which indicates that
cervical exfoliated cells can be used for the detection of telomerase
activity. It will help in easy screening of women for telomerase
activity along with Pap test in the same scraped cervical cells.
Possible inhibition of the TRAP assay by the presence of normal
cervical cells is not going to interfere with sensitivity of the
assay since Kyo et al (1997) observed that the detection limit of
TRAP assay was 100 cancer cells. Furthermore, Wisman et al
(2001) successfully assayed telomerase activity even in 10 cervical
cells.
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We observed a positive association between telomerase activity
and infection with HR-HPV type 16/18. These findings are in
accordance with earlier reports (Zheng et al, 1997), which suggest
telomerase activation as an early event occurring during cervical
neoplastic transformation and HPV infection (Yashima et al,
1998). Consequently, monitoring telomerase activity could also
have potential prognostic significance.
When we assessed association of HR-HPV types 16 and 18 with
telomerase activity, we observed that, of seven samples of mild
dysplasia that were positive for telomerase activity, six of these
were positive for HR-HPV type 16 and one for low risk HPV type
11. Absence of telomerase activity in four mild dysplasia samples
suggests that they belong to those groups of cases who may not
progress since there are some percentages of dysplastic lesions,
which revert back to normalcy. During the study of biology of low-
grade squamous intraepithelial lesions (LSILs) using PCR based
clonality assay, Park et al (1996) revealed that LSILs include two
types of lesions that are biologically distinct; one is monoclonal
and associated with malignant HPV types while the other is
polyclonal and associated with other HPV types. As monoclonality
is a hallmark of neoplasia irrespective of organ type, the lesions
that express telomerase activity appears to have the characteristics
of neoplastic lesions. As reactivation of telomerase activity is
linked with malignancy, a follow-up of these samples only can
determine the fate of these samples. Weak telomerase activity in
seven normal cervical scrapes which were positive for HR-HPV
types 16 and 18 makes an interesting observation. The cytology
reports for these samples were inflammation (n¼ 2) and ASC-US
(n¼ 1) and the colposcopic examination revealed cervical erosion
in four cases. This is in agreement with earlier studies that showed
presence of mild telomerase activity even in ASC-US, inflammation
and cervical erosions (Kyo et al, 1997; Shroyer et al, 1998; Wisman
et al, 2000). It is also known that the presence of HPV 16 E6
protein can activate telomerase activity irrespective of cells
entering ‘crisis’ stage (Klingelhutz et al, 1996).
It has been established that there is variation in the interpreta-
tion of ASC-US Pap smears even among expert cytopathologists
(Sherman et al, 1994). ASC-US/LSIL Triage Study (ALTS)
recommends HPV DNA testing in women with ASC-US but not
in LSIL (Sherman et al, 2002). This brings forth the debate over the
subject that whether all women with abnormal cervical smear
should be referred and treated (Flannelly and Kitchener, 1995). It
may look too radical since only 1% of women with CIN I are
estimated to progress to invasive cervical cancer (Holowaty et al,
1999). In addition, identifying women with abnormal cervical
changes put such women under stress that they are at a risk of
developing cervical cancer, when in fact majority of them never
develop the disease (Raffle et al, 1995). The presence of telomerase
activity in the whole range of cervical samples from mild dysplasia
to stage IV cancers suggests that telomerase is activated early and
play an essential role during cervical carcinogenesis. The average
telomerase activity increased with the progression of the clinical
stage. The gradual elevation of telomerase activity from mild to
moderate to high to very high telomerase activity in different
dysplsia and invasive cancer samples indicate that with the
progression of the disease there is a concomitant increase in the
telomerase activity (Kyo et al, 1997; Shroyer et al, 1998: Wisman
et al, 2001; Baege et al, 2002).
The levels of hTERT mRNA expression complemented well with
the telomerase activity levels observed in different grades of
cervical lesions to invasive cervical cancer samples. One mild
dysplasia sample, which was negative for telomerase activity,
expressed hTERT. This may be explained due to the upregulation
of hTERT before the reactivation of telomerase activity. Similar
observations were made in other cancers including cervical cancer
by several authors (Kyo et al, 1997; Nakano et al, 1998; Shroyer
et al, 1998; Wisman et al, 2001).
It is remarkable that high rates of cervical cancer deaths still
occur despite the fact that cervical cancer is an excellent model for
early detection due to long interval between the time of infection
or initial lesions and development of invasive cancer with a well-
known natural history. Early identification and intervention
should have a significant impact on the reduction of cervical cancer
morbidity and mortality. Identification of women at risk for cervical
cancer would not only minimise the unnecessary follow-up visits a
woman has to undergo, but would also avoid invasive procedures
without compromising on the disease detection. We suggest that
telomerase activation is a relatively early-stage event in cervical
carcinogenesis, and this activation is associated with the initiation
and progression of cervical lesions. Detection of telomerase activity
may serve as a tool for reliable diagnosis and prognosis of cervical
neoplasias along with cytology and HPV testing.
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